Optimi Health Signs Two New Supply Agreements In Less Than a Week
Optimi (OPTHF), the Canadian, home-grown mushroom formulations producer has signed not one but two supply deals with different research companies.
atai Life Sciences: Unparalleled Diversification With 10 Psychedelic Compounds Going Into Clinical Trials In 2022
In the speculative world of ‘psychedelic’ biotech, companies that are under-capitalized or lacking pipeline diversity face an uphill battle to reach the finish line.
High Hopes For Alcohol Use Disorder Treatment: Clearmind’s Successful Pre-IND Meeting With The FDA
The meeting, which took place on May 18 between the psychedelic pharmaceutical biotech company Clearmind Medicine Inc. (CMNDF) and the US Food and Drug Administration marks the completion the pre-IND New Drug Application stage.
Optimi Completes First Grow of Psilocybin Mushrooms, Introduces New Head Of Cultivation
Optimi Health Corp. (OPTHF), the Canadian company that produces homegrown and scalable mushrooms accessible to all, announces big step towards commercialization. It has successfully completed its first batch of psilocybin cubensis and functional mushrooms and is ready for supply agreements and direct work with physicians.
Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company
Medical Psychedelics have made it into Davos, just in time for the World Economic Forum.
Psychedelic Treatment For Alcoholism? Clearmind Medicine And SciSparc Collaboration Yields Positive Results
Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, revealed positive safety profile results from its joint pre-clinical trial with SciSparc Ltd.
Christian Angermayer Bullish On Psychedelic Sector And Life Extension Technology
In this week’s Trade To Black Podcast, TDR Founder Shadd Dales and lead financial writer Benjamin A. Smith interview the founder of Apeiron Investment Group, Christian Angermayer.
MindMed Appoints Schond L. Greenway As CFO
Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.
Irwin Naturals Completes Acquisition Of Ketamine Health Centers
Irwin Naturals (OTCQB: IWINF) (FRA:97X) has completed the acquisition of KHC Capital Group, LLC.
Patents In The Psychedelics Space: Good Or Bad? It’s Complicated, Here’s What The Experts Say
Patents are the golden eggs of the booming psychedelic space.